Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.
COPD
COSYCONET cohort
chronic obstructive pulmonary disease
clinical respiratory medicine
cytokine
hyperinflation
inflammation
respiratory function tests
Journal
Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
12
06
2024
accepted:
02
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
24
10
2024
Statut:
aheadofprint
Résumé
Chronic obstructive pulmonary disease (COPD) exhibits diverse patterns of disease progression, due to underlying disease activity. We hypothesized that changes in static hyperinflation or KCO % predicted would reveal subgroups with disease progression unidentified by preestablished markers (FEV Analysing data of 1364 patients from the German observational COSYCONET-cohort, disease progression and improvement patterns were assessed for their impact on mortality via Cox hazard regression models. Association of biomarkers and COPD Assessment test items with phenotypes of disease progression or improvement were evaluated using logistic regression and random forest models. Increased risk of 18-54-month mortality was linked to decrease in KCO % predicted (7.5% increments) and FEV In a multicentric cohort of COPD, new markers of current disease activity predicted mid-term mortality and could not be anticipated by baseline biomarkers.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Chronic obstructive pulmonary disease (COPD) exhibits diverse patterns of disease progression, due to underlying disease activity. We hypothesized that changes in static hyperinflation or KCO % predicted would reveal subgroups with disease progression unidentified by preestablished markers (FEV
METHODS
METHODS
Analysing data of 1364 patients from the German observational COSYCONET-cohort, disease progression and improvement patterns were assessed for their impact on mortality via Cox hazard regression models. Association of biomarkers and COPD Assessment test items with phenotypes of disease progression or improvement were evaluated using logistic regression and random forest models.
RESULTS
RESULTS
Increased risk of 18-54-month mortality was linked to decrease in KCO % predicted (7.5% increments) and FEV
CONCLUSION
CONCLUSIONS
In a multicentric cohort of COPD, new markers of current disease activity predicted mid-term mortality and could not be anticipated by baseline biomarkers.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Von-Behring-Röntgen-Stiftung
ID : 66-LV07
Organisme : Hessisches Ministerium für Wissenschaft und Kunst (LOEWE Habitat)
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB/TR-84 TP C01
Organisme : Deutsches Zentrum für Lungenforschung
ID : 82DZLI05C2
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research; BMBF)
ID : FKZ 01ZZ2318A
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research; BMBF)
ID : 01 GI 0881
Organisme : PermedCOPD
ID : FKZ 01EK2203A
Organisme : ERACoSysMed2-SysMed-COPD
ID : FKZ 031L0140
Investigateurs
Stefan Andreas
(S)
Robert Bals
(R)
Jürgen Behr
(J)
Kathrin Kahnert
(K)
Thomas Bahmer
(T)
Burkhard Bewig
(B)
Ralf Ewert
(R)
Beate Stubbe
(B)
Joachim H Ficker
(JH)
Christian Grohé
(C)
Matthias Held
(M)
Markus Henke
(M)
Felix Herth
(F)
Anne-Marie Kirsten
(AM)
Henrik Watz
(H)
Rembert Koczulla
(R)
Juliane Kronsbein
(J)
Cornelia Kropf-Sanchen
(C)
Christian Herzmann
(C)
Michael Pfeifer
(M)
Winfried J Randerath
(WJ)
Werner Seeger
(W)
Michael Studnicka
(M)
Christian Taube
(C)
Hartmut Timmermann
(H)
Peter Alter
(P)
Bernd Schmeck
(B)
Claus Vogelmeier
(C)
Tobias Welte
(T)
Hubert Wirtz
(H)
Informations de copyright
© 2024 The Author(s). Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Références
Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10:447–458.
Agusti A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023;2023:61.
Casanova C, de Torres JP, Aguirre‐Jaime A, Pinto‐Plata V, Marin JM, Cordoba E, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184:1015–1021.
Lange P, Ahmed E, Lahmar ZM, Martinez FJ, Bourdin A. Natural history and mechanisms of COPD. Respirology. 2021;26:298–321.
Vogelmeier CF, Román‐Rodríguez M, Singh D, Han MK, Rodríguez‐Roisin R, Ferguson GT. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020;166:105938.
Singh D, Criner GJ, Naya I, Jones PW, Tombs L, Lipson DA, et al. Measuring disease activity in COPD: is clinically important deterioration the answer? Respir Res. 2020;21:134.
Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68:687–690.
Kolsum U, Damera G, Pham TH, Southworth T, Mason S, Karur P, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140:1181.e7–1184.e7.
Vedel‐Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen general population study. Am J Respir Crit Care Med. 2016;193:965–974.
Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed—urgently. Am J Respir Crit Care Med. 2010;182:863–864.
Celli B, Locantore N, Yates JC, Bakke P, Calverley PMA, Crim C, et al. Markers of disease activity in COPD: an 8‐year mortality study in the ECLIPSE cohort. Eur Respir J. 2021;57:2001339.
Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648.
Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–1192.
Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52.
Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 Suppl B:25–31. discussion 3–7.
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline LN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–654.
Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six‐minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body‐mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–1012.
Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111–124.
Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2:75–79.
Naya IP, Tombs L, Muellerova H, Compton C, Jones PW. Long‐term outcomes following first short‐term clinically important deterioration in COPD. Respir Res. 2018;19:222.
Solem CT, Sun SX, Sudharshan L, Macahilig C, Katyal M, Gao X. Exacerbation‐related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:641–652.
Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, et al. Exacerbations and lung function decline in COPD: new insights in current and ex‐smokers. Respir Med. 2007;101:1305–1312.
Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85–91.
Larsson K, Janson C, Lisspers K, Stallberg B, Johansson G, Gutzwiller FS, et al. The impact of exacerbation frequency on clinical and economic outcomes in Swedish COPD patients: the ARCTIC study. Int J Chron Obstruct Pulmon Dis. 2021;16:701–713.
Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891–2908.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal‐Singer R, et al. Evaluation of CLtIPSEI. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138.
Park J, Lee CH, Lee YJ, Park JS, Cho YJ, Lee JH, et al. Longitudinal changes in lung hyperinflation in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:501–508.
Kim YW, Lee CH, Hwang HG, Kim YI, Kim DK, Oh YM, et al. Decline in carbon monoxide transfer coefficient in chronic obstructive pulmonary disease. J Clin Med. 2020;9:1512.
Hughes JM, Pride NB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med. 2012;186:132–139.
Shimizu K, Konno S, Makita H, Kimura H, Kimura H, Suzuki M, et al. Transfer coefficients better reflect emphysematous changes than carbon monoxide diffusing capacity in obstructive lung diseases. J Appl Physiol. 1985;2018(125):183–189.
Augustin IML, Spruit MA, Houben‐Wilke S, Franssen FME, Vanfleteren L, Gaffron S, et al. The respiratory physiome: clustering based on a comprehensive lung function assessment in patients with COPD. PLoS One. 2018;13:e0201593.
Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37.
Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW, et al. Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J. 2017;50:50.
Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580–586.
Agusti A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med. 2023;207:819–837.
Davidson‐Pilon C. Lifelines: survival analysis in python. J Open Source Softw. 2019;4:4.
Hartman JE, Ten Hacken NH, Klooster K, Boezen HM, de Greef MH, Slebos DJ. The minimal important difference for residual volume in patients with severe emphysema. Eur Respir J. 2012;40:1137–1141.
Seabold S, Perktold J. Statsmodels: econometric and statistical modeling with python. Proceedings of the 9th python in science conference. 2010.
Buitinck L, Louppe G, Blondel M, Pedregosa F, Mueller A, Grisel O, et al. API design for machine learning software: experiences from the scikit‐learn project. ECML PKDD Workshop: Languages for Data Mining and Machine Learning. 2013: 108–22.
Celli BR, Decramer M, Lystig T, Kesten S, Tashkin DP. Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res. 2012;13:66.
O'Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev. 2006;15:61–67.
Langer D, Ciavaglia CE, Neder JA, Webb KA, O'Donnell DE. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med. 2014;8:731–749.
French A, Balfe D, Mirocha JM, Falk JA, Mosenifar Z. The inspiratory capacity/total lung capacity ratio as a predictor of survival in an emphysematous phenotype of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1305–1312.
Lim JU, Lee JS, Lee JH, Lee SD, Oh YM, Rhee CK, et al. Clinical impact of long‐term change in air trapping on pulmonary function and computed tomography parameters in chronic obstructive pulmonary disease. Korean J Intern Med. 2021;36:636–646.
Huang H, Huang X, Zeng K, Deng F, Lin C, Huang W. Interleukin‐6 is a strong predictor of the frequency of COPD exacerbation within 1 year. Int J Chron Obstruct Pulmon Dis. 2021;16:2945–2951.
Zemans RL, Jacobson S, Keene J, Kechris K, Miller BE, Tal‐Singer R, et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017;18:117.
Celli BR, Locantore N, Yates J, Tal‐Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1065–1072.
Oh AS, Baraghoshi D, Lynch DA, Ash SY, Crapo JD, Humphries SM, et al. Emphysema progression at CT by deep learning predicts functional impairment and mortality: results from the COPDGene study. Radiology. 2022;304:672–679.
Pompe E, Strand M, van Rikxoort EM, Hoffman EA, Barr RG, Charbonnier JP, et al. Five‐year progression of emphysema and air trapping at CT in smokers with and those without chronic obstructive pulmonary disease: results from the COPDGene study. Radiology. 2020;295:218–226.